22.418 articles found

Adverse events from the treatment of Parkinson's disease.

Chou KL.

Neurol Clin · 2008-08-01

DOI: 10.1016/j.ncl.2008.05.003PMID: 18774443

16th Symposium on the Treatment of Parkinson's Disease, September 15, 2007, Tokyo, Japan. Preface.

Yoshikuni Mizuno, MD, Kazuko Hasegawa, MD.

J Neurol · 2008-08-01

DOI: 10.1007/s00415-008-4001-xPMID: 18821079

USE OF GENOMIC TESTING AND KETOGENIC COMPOUNDS FOR TREATMENT OF REDUCED COGNITIVE FUNCTION

HENDERSON SAMUEL T.

· 2008-07-31

Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia.

Lefaucheur JP, Gurruchaga JM, Pollin B, von Raison F, Mohsen N, Shin M, Ménard-Lefaucheur I, Oshino S, Kishima H, Fénelon G, Rémy P, Cesaro P, Gabriel I, Brugières P, Keravel Y, Nguyen JP.

Eur Neurol · 2008-07-31

DOI: 10.1159/000148246PMID: 18667827

Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease.

Adams F, Boschmann M, Lobsien E, Kupsch A, Lipp A, Franke G, Leisse MC, Janke J, Gottschalk S, Spranger J, Jordan J.

Eur J Clin Pharmacol · 2008-07-30

DOI: 10.1007/s00228-008-0532-4PMID: 18665357

Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.

Glavan G.

Brain Res · 2008-07-29

DOI: 10.1016/j.brainres.2008.07.071PMID: 18721798

Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease.

Park HJ, Lee PH, Bang OY, Lee G, Ahn YH.

J Neurochem · 2008-07-28

DOI: 10.1111/j.1471-4159.2008.05589.xPMID: 18665911

THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS

GALLEY GUIDO, GROEBKE ZBINDEN KATRIN, NORCROSS ROGER, STALDER HENRI.

· 2008-07-24

THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS

GALLEY GUIDO, GROEBKE ZBINDEN KATRIN, NORCROSS ROGER, STALDER HENRI.

· 2008-07-24

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Bordia T, Campos C, Huang L, Quik M.

J Pharmacol Exp Ther · 2008-07-23

DOI: 10.1124/jpet.108.140897PMID: 18650244

Potassium channels: possible new therapeutic targets in Parkinson's disease.

Wang Y, Yang PL, Tang JF, Lin JF, Cai XH, Wang XT, Zheng GQ.

Med Hypotheses · 2008-07-22

DOI: 10.1016/j.mehy.2008.05.021PMID: 18650029

Assay for Parkinson's Disease therapeutics

JOHNSTON JENNIFER A.

· 2008-07-21